A Phase 4 interventional study of Bronchodilators inhalation and Placebo in COPD, sponsored by Dr. J. Alberto Neder. Recruiting at 1 site in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-02-13.
Sponsored by Dr. J. Alberto Neder · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada — 40 open to participants now, 49 under way, 9 of them phase 3. Pulmonary Disease, Chronic Obstructive · Canada.
Among the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada, this one is the 274th largest by planned enrollment of the 340 interventional ones that give a count, is one of 12 that started in 2024, is one of 42 in phase 4, reaches primary completion later than 20 of the 48 other live ones, and was the 378th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →40 of the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Canada, United States, Argentina and 15 more countries
Ages 40–75
Expedition Therapeutics, Inc · Sites in Canada, United States, Georgia and 1 more country
Ages 40–85
University of British Columbia · Sites in Canada
Ages 19–80 · Healthy volunteers
Western University, Canada · Sites in Canada
Ages 50–85
Pfizer · Sites in Canada, United States, Argentina and 15 more countries
Ages 35–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
398 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 59 · Phase 3 122 · Phase 4 42
First in 2000; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 207 across the 340 interventional studies, 115 across the 57 observational. Of the 313 that completed or were terminated, 133 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
184 of 398 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr. J. Alberto Neder as lead sponsor.
Dr. J. Alberto Neder has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
12 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT05543720University Health Network, TorontoEvaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study | 2026-12 |
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT06969573University of AlbertaInhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD | 2026-12-31 |
| NCT06825013Dr. J. Alberto NederBronchodilators and Lung Mechanics During Exercise in COPD | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 398 studies in Pulmonary Disease, Chronic Obstructive with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bronchodilators are medications that open the bronchi to help patients with COPD to breathe better. It is still not known exactly how this effect improves shortness of breath in people with COPD. The goal of this clinical trial is to determine whether bronchodilators lower resistance in the smallest airways in the lungs, and whether this will improve the feeling of breathlessness in these patients.
The main questions the investigators attempt to answer are:
The investigators will compare short-acting bronchodilators to placebo (a substance that contains no drug) to see if the bronchodilator medications improve small airway resistance and breathlessness during exercise.
Participants will:
Small airways disease is a major cause of increased airway resistance and obstruction in chronic obstructive pulmonary disease (COPD). Small airways are those airways beyond generation 8 that are \<2 mm in diameter. Due to lung geometry and the mechanism of particle deposition, treatment of small airway disease is challenging and a major clinical concern. Recent advances in respiratory medication delivery devices have purported to improve delivery of medication to the small airways, thus providing better physiologic and symptomatic relief. One such example is Breztri™ Aerosphere©, is a pressurized metered-dose inhaler (pMDI) that delivers triple therapy (long-acting beta-2 agonist, long-acting muscarinic antagonist, and an inhaled corticosteroid), and is currently approved in Canada for patients with COPD. Preliminary evidence has suggested that this product reduced mortality risk and had beneficial effects on exertional dyspnea (shortness of breath), notably in symptomatic patients who have been treated with dry powder inhalers (DPIs). Modeling studies have shown better deposition of drug into the small airways with the pMDI than the DPI; however, it remains unclear whether improved deposition is sufficient to improve small airways function in patients with COPD, and whether these changes result in commensurate improvement in dyspnea and exercise tolerance. Uncovering the mechanisms of dyspnea improvement is a crucial step to provide evidence-based rationale for using pMDI to mitigate the burden of this key patient reported outcome.
Dyspnea during exercise (exertion) in COPD arises when the drive to breathe (neural) is not properly rewarded by the output of the lungs (respiratory mechanics), a phenomenon called "neuromechanical dissociation". In patients with moderate-to-severe COPD, this 'neuromechanical dissociation' is largely a result of impairment in the function of the small airways (airways that are \<2mm in diameter) which conspire to induce pulmonary gas trapping and, consequently, increase lung volumes ("hyperinflation"). During exercise when ventilatory demands increase, the reduced time constant for lung emptying (i.e., impaired expiratory time due to increased breathing frequency) leads to acute-on-chronic lung hyperinflation which accelerates attainment of critical inspiratory constraints (i.e., tidal volume expansion is limited), and thus, patients have significantly greater dyspnea and earlier exercise termination. It is reasonable to assume that any inhaled medication for COPD with enhanced access to the small airways could reduce or delay dynamic hyperinflation during exercise and improve a patient's shortness of breath.
MAIN RESEARCH QUESTION In patients with COPD and significant resting lung hyperinflation, does acute treatment with a short-acting bronchodilator (salbutamol sulfate + ipratropium bromide) improve impulse oscillometry derived small airway resistance during cardiopulmonary exercise compared to placebo.
SECONDARY RESEARCH QUESTIONS In patients with COPD and significant resting lung hyperinflation, does acute treatment with short-acting bronchodilator (salbutamol sulfate + ipratropium bromide) improve exertional dyspnea and exercise tolerance during cardiopulmonary exercise compared to placebo. Are improvements in small airway resistance, associated with a reduction in inspiratory neural drive and improved lung mechanics, as measured by diaphragm electromyography (EMGdi).
RESEARCH METHODS Study design: This is a single center, investigator-initiated, prospective, cross over study being conducted over 2-3 weeks.
Study outline:
After giving written informed consent, all participants will be asked to complete 3 visits to the Respiratory Investigation Unit, Kingston General Hospital. Each visit will be conducted at the same time, in the morning, 2 to 7 days apart.
Visit 1 (eligibility assessment): Detailed medical history, physical examination and ECG will be performed. Participants will perform complete pulmonary function testing including spirometry, plethysmography, diffusing capacity for carbon monoxide (DLCO), small airway function assessment (impulse oscillometry (IOS), single-breath and multiple-breath nitrogen washout tests). Participants will complete a symptom-limited incremental cardiopulmonary exercise test (CPET) to determine maximum exercise capacity. PFT and CPET procedures will be conducted according to consensus recommendations.
Visit 2/3 (Constant Work Rate Cardiopulmonary Exercise Test with Placebo or Bronchodilator): Spirometry, body plethysmography, impulse oscillometery, and static and dynamic lung compliance measurements will be performed pre-intervention and 15 minutes post intervention (either dual short-acting bronchodilator (salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg) or a placebo (normal saline)). Participants will then perform a constant work rate tests at 75% peak exercise capacity (determined at V1). Participant will perform exercise on a stationary bicycle while breathing through a mouthpiece with nose clips on, which allows for the breath-by-breath recording of ventilatory and metabolic variables throughout exercise. After approximately 6 minutes of relaxed, baseline breathing, participants will be asked to pedal for 1 minute against no resistance to warm up. The load will then increase to constant work rate (determined at V1), participants will continue to pedal until symptom limitation. Every 2 minutes during exercise, the participant will perform an impulse oscillometery test for assessment of small airways function, followed by an inspiratory capacity maneuver to determine lung volumes. Respiratory discomfort (dyspnea) and leg fatigue will be assessed using the modified Borg 0-10 scale. Vital signs (BP, HR, SpO2) will be monitored throughout each exercise test and during recovery.
Diaphragm EMG and Respiratory Pressure Measurements: At the beginning of Visit 2 and 3, the investigators will apply a topical anesthetic spray to the nasal passages and throat of the participant. A thin catheter (diameter 2 mm) will be inserted by the investigator through the nose down the throat and into the esophagus and top part of stomach. This catheter measures the electric activity (EMG) of the diaphragm, which provides a surrogate measurement of the inspiratory neural drive to breathe. It also measures pressures in the esophagus within the chest as well as in the stomach, which gives useful information about the work of breathing and breathing mechanics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a combination short-acting bronchodilator (Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)) via nebulizer.
Drug: Bronchodilators inhalation
Participants will receive normal saline via nebulizer.
Drug: Placebo
Salbutamol sulphate (2.5 mg) + ipratropium bromide (0.5 mg)
Nebulized saline
Airway resistance
Primary objective is to measure airway resistance measured by impulse oscillometry at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).
Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise
Inspiratory neural drive
Secondary objective is to measure inspiratory neural drive (IND) by diaphragm activation (EMGdi%max) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).
Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise
Esophageal Pressure (Pes)
Secondary objective is to measure esophageal pressure (Pes) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).
Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise
Gastric Pressure (Pga)
Secondary objective is to measure gastric pressure (Pga) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).
Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise
Trans-diaphragmatic Pressure (Pdi)
Secondary objective is to measure trans-diaphragmatic pressure (Pdi) at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).
Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise
Operating lung volumes
Secondary objective is to measure inspiratory capacity at isotime (maximum exercise time achieved by all participants) during cardiopulmonary exercise testing (cycle ergometer).
Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise
Exertional dyspnea
Primary objective is to measure perceptual (e.g. intensity of dyspnea) responses at isotime (maximum exercise time achieved by all participants) during a standardized cardiopulmonary exercise testing (cycle ergometer).
Time frame: At 2, 4, 6, 8, and 10 minutes from start of exercise
Exercise tolerance
Exercise tolerance will be assessed as the time from start of loaded pedaling to end of loaded exercise.
Time frame: Within 10-12 min from start of cardiopulmonary exercise test
Plan to share: Yes — Data will not be shared until completion of the trial and final analysis. Anonymized data may be made available upon reasonable request after appropriate ethical approval and institutional data sharing agreements
Supporting information: Study protocol
Time frame: Data will not be released until study completion (anticipated January 2027).
Access criteria: Data will be released on reasonable request after appropriate ethical approval, anonymization, and data sharing agreements to ensure data integrity and participant privacy.
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 26 months after the start.
Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 26 months is below that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →